Erica Schleifman
Senior Director, Cancer Biomarker Development AstraZeneca
Erica Schleifman serves as Senior Director, Cancer Biomarker Development at AstraZeneca, where she leads strategic initiatives to accelerate biomarker-driven oncology development across global programmes. A solution-driven leader, she brings extensive experience building and guiding cross-functional collaborations that translate complex science into measurable clinical and commercial impact.
Previously at Genentech and Roche, Erica led enterprise-level initiatives spanning translational research, biomarker strategy and drug development, managing significant budgets and navigating complex stakeholder environments. She is known for aligning diverse teams around shared priorities, breaking down silos and delivering innovative solutions that advance precision oncology.
Combining deep scientific expertise with strong business acumen, Erica thrives in matrixed organisations, turning strategic vision into executable action.
Seminars
- Turning ctDNA and MRD signals into faster, higher confidence go/no-go decisions across modalities
- Cutting years and cost from development by replacing slow endpoints with early molecular insight
- Making liquid biopsy work in the real world: global logistics, scalability, and ROI for sponsors
